© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
April 23rd 2021, 12:45am
The findings come from the group’s review of over 30 years’ worth of research of the presence of autoimmune cytopenias and autoimmune diseases in lymphoid and myeloid neoplasms.
April 17th 2021, 1:00am
The researchers credit wider availability of molecular testing and better understanding of the diseases for the emerging targeted therapies in development.
April 9th 2021, 11:00am
Patients who cut their calorie intake by at least 10% and exercised modestly were 70% less likely to have remaining leukemic cells in their bone marrow 1 month after starting chemotherapy, according to results of an early study.
April 3rd 2021, 3:30pm
Reversible Bruton tyrosine kinase (BTK) inhibitors may play a key role in treatment when it comes to addressing resistance stemming mutations in the active site (Cys481) that emerge from treatment with irreversible BTK inhibitors.
April 3rd 2021, 10:30am
Classical mantle cell lymphoma (MCL) and 2 aggressive variants exhibited similar rates of negativity for the CD5 marker, but further testing may be needed in certain cases to avoid misdiagnosis with diffuse large B-cell lymphoma (DLBCL).
March 31st 2021, 2:24pm
Pfizer/BioNTech’s COVID-19 vaccine appears to be 100% effective at preventing adolescent infections; Vyxeos approved for pediatric secondary acute myeloid leukemia (AML); study results show a 62% drop in pediatric respiratory illness over the past year.
March 24th 2021, 9:07pm
More than two-thirds of patients with chronic lymphocytic leukemia (CLL) survived at least 2 years but were highly susceptible to adverse events (AEs), in a recent study.
March 19th 2021, 8:20pm
A survey released this month of US patients with blood cancers shows a somewhat surprising level of hesitancy about receiving a COVID-19 vaccine, but because patients with cancer were not included in clinical trials, the situation for this population is somewhat nuanced.
March 15th 2021, 6:38pm
Study findings shed a light on the role of minimal residual disease (MRD) status and type of postremission therapy in the prognosis of patients with intermediate-risk acute myeloid leukemia (AML) who do not have FLT3-ITD, NPM1, and biallelic CEBPA mutations.
March 12th 2021, 5:30pm
Whole-genome sequencing (WGS) is at least as accurate as conventional tests when it comes to genomic profiling in patients with acute myeloid leukemia and myelodysplastic syndromes.